MindWalk (NASDAQ:HYFT) Announces Earnings Results

Key Points

• MindWalk reported a quarterly loss of $0.09 per share, missing the consensus estimate of a $0.05 loss by $0.04. The company posted a negative net margin of 89.65% and a negative return on equity of 92.61%.
• Shares traded up $0.03 to $1.33, with a market capitalization of approximately $62.1 million. The stock has ranged from $0.99 to $2.99 over the past 52 weeks.
• Analyst sentiment is mixed, resulting in an overall “Hold” rating and an average price target of $5.00. Ratings include one Strong Buy, two Buys, and two Sells.

MindWalk (NASDAQ:HYFT - Get Free Report) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04), Zacks reports. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%.

MindWalk Stock Performance

NASDAQ HYFT traded up $0.03 during trading hours on Monday, hitting $1.33. 171,103 shares of the company's stock traded hands, compared to its average volume of 358,475. The business's fifty day moving average price is $1.38 and its two-hundred day moving average price is $1.36. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $62.12 million, a P/E ratio of -6.05 and a beta of 0.82. MindWalk has a 52 week low of $0.99 and a 52 week high of $2.99.

Analyst Upgrades and Downgrades

HYFT has been the subject of several research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of MindWalk in a report on Wednesday, July 15th. Zacks Research cut shares of MindWalk from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 28th. Wall Street Zen raised shares of MindWalk from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, HC Wainwright reiterated a "buy" rating on shares of MindWalk in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat, MindWalk has an average rating of "Hold" and an average price target of $5.00.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.